LEADER 06948nam 22013093u 450 001 9910139613803321 005 20220913234956.0 010 $a1-283-20363-4 010 $a9786613203632 010 $a0-470-92935-9 010 $a0-470-92934-0 035 $a(CKB)2550000000042753 035 $a(EBL)818637 035 $a(OCoLC)746598445 035 $a(SSID)ssj0000534041 035 $a(PQKBManifestationID)12165841 035 $a(PQKBTitleCode)TC0000534041 035 $a(PQKBWorkID)10493413 035 $a(PQKB)10894419 035 $a(MiAaPQ)EBC818637 035 $a(PPN)190360267 035 $a(EXLCZ)992550000000042753 100 $a20131230d2011|||| u|| | 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 10$aAntiviral Drugs$b[electronic resource] $eFrom Basic Discovery Through Clinical Trials 210 $aHoboken $cWiley$d2011 215 $a1 online resource (470 p.) 300 $aDescription based upon print version of record. 311 $a1-118-25122-9 311 $a0-470-45563-2 327 $aANTIVIRAL DRUGS; CONTENTS; CONTRIBUTORS; PREFACE; PART I HUMAN IMMUNODEFICIENCY VIRUS; 1 Discovery and Development of Atazanavir; 2 Discovery and Development of PL-100, A Novel HIV-1 Protease Inhibitor; 3 Darunavir (Prezista, TMC114): From Bench to Clinic, Improving Treatment Options for HIV-Infected Patients; 4 Discovery and Development of Tipranavir; 5 TMC278 (Rilpivirine): A Next-Generation NNRTI in Phase III Clinical Development for Treatment-Naive Patients; 6 Etravirine: From TMC125 to Intelence: A Treatment Paradigm Shift for HIV-Infected Patients 327 $a7 Discovery and Development of Tenofovir Disoproxil Fumarate8 Discovery and Development of Apricitabine; 9 Discovery and Development of Maraviroc and PF-232798: CCR5 Antagonists for the Treatment of HIV-1 Infection; 10 Discovery of the CCR5 Antagonist Vicriviroc (Sch 417690/Sch-D) for the Treatment of HIV-1 Infection; 11 Discovery and Development of HIV-1 Entry Inhibitors That Target gp120; 12 Discovery of MK-0536: A Potential Second-Generation HIV-1 Integrase Strand Transfer Inhibitor with a High Genetic Barrier to Mutation; 13 Discovery and Development of HIV Integrase Inhibitor Raltegravir 327 $a14 Elvitegravir: A Novel Monoketo Acid HIV-1 Integrase Strand Transfer InhibitorPART II HEPATITIS C VIRUS; 15 Discovery and Development of Telaprevir; 16 Discovery and Development of BILN 2061 and Follow-up BI 201335; 17 Intervention of Hepatitis C Replication Through NS3-4A, the Protease Inhibitor Boceprevir; 18 Discovery and Development of the HCV NS3/4A Protease Inhibitor Danoprevir (ITMN-191/RG7227); 19 Discovery and Development of the HCV Protease Inhibitor TMC435; 20 Discovery and Clinical Evaluation of the Nucleoside Analog Balapiravir (R1626) for the Treatment of HCV Infection 327 $a21 Discovery and Development of PSI-6130/RG712822 Discovery of Cyclophilin Inhibitor NIM811 as a Novel Therapeutic Agent for HCV; 23 HCV Viral Entry Inhibitors; PART III RESPIRATORY SYNCYTIAL VIRUS INHIBITORS; 24 Discovery of the RSV Inhibitor TMC353121; 25 Discovery and Development of Orally Active RSV Fusion Inhibitors; 26 Discovery and Development of RSV604; PART IV INFLUENZA, HEPATITIS B, AND CYTOMEGALOVIRUS INHIBITORS; 27 Discovery and Development of Influenza Virus Sialidase Inhibitor Relenza; 28 Discovery and Development of Entecavir 327 $a29 Benzimidazole Ribonucleosides: Novel Drug Candidates for the Prevention and Treatment of Cytomegalovirus DiseasesINDEX; Color Plate 330 $aThis book focuses on new small molecule approaches to combat viral infections. The chapters describe the discovery and development from bench through the clinic of relatively recently-approved antiviral drugs and compounds in advanced clinical development. Organized by a virus (such as HIV, HCV, RSV, influenza, HBV and CMV) and written by top academic and industrial authorities in the field, the book provides a unique opportunity to study, understand and apply discovery and development principles and learning without the need for an individual to research, analyze and synthesize all immense so 606 $aAntiviral Agents -- therapeutic use 606 $aAntiviral agents 606 $aClinical Trials as Topic 606 $aDrug Discovery 606 $aDrug Evaluation 606 $aAntiviral agents 606 $aEpidemiologic Studies 606 $aChemistry, Pharmaceutical 606 $aEvaluation Studies as Topic 606 $aInvestigative Techniques 606 $aAnti-Infective Agents 606 $aEpidemiologic Methods 606 $aPharmacology 606 $aTherapeutic Uses 606 $aHealth Care Evaluation Mechanisms 606 $aChemistry 606 $aBiological Science Disciplines 606 $aNatural Science Disciplines 606 $aQuality of Health Care 606 $aPublic Health 606 $aPharmacologic Actions 606 $aEnvironment and Public Health 606 $aHealth Care Quality, Access, and Evaluation 606 $aChemical Actions and Uses 606 $aHealth Care 606 $aClinical Trials as Topic 606 $aDrug Discovery 606 $aAntiviral Agents 606 $aDrug Evaluation 606 $aHealth & Biological Sciences$2HILCC 606 $aPharmacy, Therapeutics, & Pharmacology$2HILCC 615 4$aAntiviral Agents -- therapeutic use. 615 4$aAntiviral agents. 615 4$aClinical Trials as Topic. 615 4$aDrug Discovery. 615 4$aDrug Evaluation. 615 0$aAntiviral agents 615 2$aEpidemiologic Studies. 615 2$aChemistry, Pharmaceutical 615 2$aEvaluation Studies as Topic 615 2$aInvestigative Techniques 615 2$aAnti-Infective Agents 615 2$aEpidemiologic Methods 615 2$aPharmacology 615 2$aTherapeutic Uses 615 2$aHealth Care Evaluation Mechanisms 615 2$aChemistry 615 2$aBiological Science Disciplines 615 2$aNatural Science Disciplines 615 2$aQuality of Health Care 615 2$aPublic Health 615 2$aPharmacologic Actions 615 2$aEnvironment and Public Health 615 2$aHealth Care Quality, Access, and Evaluation 615 2$aChemical Actions and Uses 615 2$aHealth Care 615 2$aClinical Trials as Topic 615 2$aDrug Discovery 615 2$aAntiviral Agents 615 2$aDrug Evaluation 615 7$aHealth & Biological Sciences 615 7$aPharmacy, Therapeutics, & Pharmacology 676 $a615/.7924 700 $aKazmierski$b Wieslaw M$0859119 702 $aKazmierski$b Wieslaw M 801 0$bAU-PeEL 801 1$bAU-PeEL 801 2$bAU-PeEL 906 $aBOOK 912 $a9910139613803321 996 $aAntiviral Drugs$91917539 997 $aUNINA